Review
Published on 04 Aug 2022
Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.981036
- 4,243 views
- 2 citations
Type at least 3 characters
2,924 articles
Articles
Original Research
Published on 04 Aug 2022
Integrated multi-omics analysis identifies ENY2 as a predictor of recurrence and a regulator of telomere maintenance in hepatocellular carcinoma
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.939948
- 3,913 views
- 8 citations
Review
Published on 04 Aug 2022
The emerging potentials of lncRNA DRAIC in human cancers
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.867670
- 2,323 views
- 8 citations
Original Research
Published on 04 Aug 2022
Oncogenic circular RNA circ_0007534 contributes to paclitaxel resistance in endometrial cancer by sponging miR-625 and promoting ZEB2 expression
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.985470
- 1,923 views
- 10 citations
Original Research
Published on 03 Aug 2022
LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.967000
- 1,630 views
- 5 citations
Original Research
Published on 03 Aug 2022
Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.933646
- 3,459 views
- 9 citations
Correction
Published on 03 Aug 2022
Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.984514
- 1,161 views
Review
Published on 03 Aug 2022
DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.943032
- 10,366 views
- 32 citations
Original Research
Published on 02 Aug 2022
Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.906415
- 2,227 views
- 4 citations
Original Research
Published on 02 Aug 2022
Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.926437
- 3,321 views
- 5 citations
Systematic Review
Published on 01 Aug 2022
CXCL5: A coachman to drive cancer progression
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.944494
- 7,099 views
- 29 citations
Original Research
Published on 01 Aug 2022
NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.967811
- 4,192 views
- 15 citations
Review
Published on 01 Aug 2022
Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.965628
- 4,479 views
- 10 citations
Review
Published on 29 Jul 2022
p53 as a biomarker and potential target in gastrointestinal stromal tumors
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.872202
- 4,684 views
- 2 citations
Original Research
Published on 29 Jul 2022
Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.910505
- 3,357 views
- 5 citations
Review
Published on 29 Jul 2022
Long non-coding RNA PVT1: A promising chemotherapy and radiotherapy sensitizer
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.959208
- 3,426 views
- 8 citations